Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.

Wang F, Zhang Z

Open source

DOI
10.1007/s11095-020-02949-y
Published
2020 Nov 20
Container
Pharmaceutical research
Publisher
Not recorded
Open access
unknown

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s11095-020-02949-y,
  title = {Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.},
  author = {Wang F and Zhang Z},
  year = {2020},
  journal = {Pharmaceutical research},
  doi = {10.1007/s11095-020-02949-y},
  url = {https://doi.org/10.1007/s11095-020-02949-y}
}

RIS

TY  - JOUR
TI  - Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
AU  - Wang F
AU  - Zhang Z
PY  - 2020
JO  - Pharmaceutical research
DO  - 10.1007/s11095-020-02949-y
UR  - https://doi.org/10.1007/s11095-020-02949-y
ER  - 

APA

F, W., & Z, Z. (2020). Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.. Pharmaceutical research. https://doi.org/10.1007/s11095-020-02949-y

Source records